AMAG Pharmaceuticals (AMAG) Releases Quarterly Earnings, Misses Estimates By $0.11 EPS
AMAG Pharmaceuticals (NASDAQ: AMAG) announced its earnings results on Friday. The company reported ($0.17) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.06) by $0.11. The company had revenue of $21.14 million for the quarter, compared to the consensus estimate of $22.54 million. During the same quarter in the prior year, the company posted ($0.87) earnings per share. The company’s quarterly revenue was up 41.9% on a year-over-year basis.
Several analysts have also recently commented on the stock. Analysts at Leerink Swann upgraded shares of AMAG Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note to investors on Friday, January 18th. They now have a $19.00 price target on the stock, up previously from $17.00. Analysts at Zacks downgraded shares of AMAG Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note to investors on Tuesday, January 1st. They now have a $18.00 price target on the stock.
Two equities research analysts have rated the stock with a buy rating, one has given a hold rating, and two have assigned a sell rating to the company. The stock has a consensus rating of “hold” and an average target price of $16.60.
Shares of AMAG Pharmaceuticals (AMAG) opened at 16.55 on Friday. AMAG Pharmaceuticals (AMAG) has a 52 week low of $12.43 and a 52 week high of $18.50. The stock’s 50-day moving average is currently $16.11. The company’s market cap is $354.4 million.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia (IDA).
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.